Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from protease inhibitors to dolutegravir and bone mineral density in HIV-1
2013-000547-85Phase 3Completed
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dolutegravir in human immunodeficiency virus infection (HIV) and low bone mineral density (2 arms), sponsored by Fight AIDS and Infectious Diseases Foundation. Primary endpoint: Change in bone mineral density by DEXA at week 48. Started Jun 2013; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)low bone mineral density
Beyond the preview
Go deeper on 2013-000547-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000547-85.